Literature DB >> 21828058

Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase.

Assia Derfoul1, Aster H Juan, Michael J Difilippantonio, Nallasivam Palanisamy, Thomas Ried, Vittorio Sartorelli.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs, which regulate gene expression by inhibiting translation or promoting degradation of specific target messenger RNAs (mRNAs). Alteration of the levels of a number of miRNAs is common in solid and hematological tumors. We have shown previously that miR-214 regulates Ezh2 in skeletal muscle and embryonic stem cells. The current study was aimed at examining the role of miR-214 in breast cancer where miR-214 levels are reduced but whether this phenomenon bears a functional relevance is unknown. MiR-214 expression was inversely correlated with Ezh2 mRNA and protein levels in breast cancer cell lines and at least one copy of the miR-214 alleles was found to be deleted in 24% (6/25) of primary breast tumors. Experimental increase of miR-214 in breast cancer cell lines correlated with reduction of Ezh2 protein levels, a known marker of invasion and aggressive breast cancer behavior. Supporting a direct targeting mechanism, miR-214 decreased luciferase activity from a construct containing the Ezh2 3' untranslated region. Expression of miR-214 specifically reduced cell proliferation of breast cancer cells and inhibited the invasive potential of a highly metastatic breast cancer cell line. These findings indicate that reduced miR-214 levels may contribute to breast tumorigenesis by allowing abnormally elevated Ezh2 accumulation and subsequent unchecked cell proliferation and invasion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828058      PMCID: PMC3204346          DOI: 10.1093/carcin/bgr184

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  35 in total

1.  E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis.

Authors:  H Müller; A P Bracken; R Vernell; M C Moroni; F Christians; E Grassilli; E Prosperini; E Vigo; J D Oliner; K Helin
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

2.  Role of histone H3 lysine 27 methylation in Polycomb-group silencing.

Authors:  Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang
Journal:  Science       Date:  2002-09-26       Impact factor: 47.728

3.  The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.

Authors:  Giuseppina Caretti; Monica Di Padova; Bruce Micales; Gary E Lyons; Vittorio Sartorelli
Journal:  Genes Dev       Date:  2004-11-01       Impact factor: 11.361

4.  Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.

Authors:  Steffen Weikert; Frank Christoph; Jens Köllermann; Markus Müller; Mark Schrader; Kurt Miller; Hans Krause
Journal:  Int J Mol Med       Date:  2005-08       Impact factor: 4.101

5.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

6.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

9.  Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells.

Authors:  Aster H Juan; Roshan M Kumar; Joseph G Marx; Richard A Young; Vittorio Sartorelli
Journal:  Mol Cell       Date:  2009-10-09       Impact factor: 17.970

10.  EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.

Authors:  Adrian P Bracken; Diego Pasini; Maria Capra; Elena Prosperini; Elena Colli; Kristian Helin
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

View more
  56 in total

1.  The Effect of miR-98 and miR-214 on Apoptotic and Angiogenic Pathways in Hepatocellular Carcinoma HepG2 Cells.

Authors:  Shaymaa M M Yahya; Shereen M M Yahya
Journal:  Indian J Clin Biochem       Date:  2019-03-11

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.

Authors:  Katsuhiko Masudo; Nobuyasu Suganuma; Hirotaka Nakayama; Takashi Oshima; Yasushi Rino; Hiroyuki Iwasaki; Kenichi Matsuzu; Kiminori Sugino; Koichi Ito; Tetsuo Kondo; Yoshiyasu Nakamura; Mitsuyo Yoshihara; Munetaka Masuda; Yohei Miyagi
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

4.  Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion.

Authors:  Amit Bera; Falguni Das; Nandini Ghosh-Choudhury; Meenalakshmi M Mariappan; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Am J Physiol Cell Physiol       Date:  2017-07-12       Impact factor: 4.249

5.  MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.

Authors:  Rui-Qing Peng; Hai-Ying Wan; Hai-Fang Li; Min Liu; Xin Li; Hua Tang
Journal:  J Biol Chem       Date:  2012-03-07       Impact factor: 5.157

6.  The Effect of Newly Synthesized Heterosteroids on miRNA34a, 98, and 214 Expression Levels in MCF-7 Breast Cancer Cells.

Authors:  Shaymaa M M Yahya; Gamal A Elmegeed; Mervat S Mohamed; Rafat M Mohareb; Mervat M Abd-Elhalim; Ghada H Elsayed
Journal:  Indian J Clin Biochem       Date:  2017-07-26

7.  miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells.

Authors:  Zheng Wang; Hao Yin; Yuanwei Zhang; Yukun Feng; Zhaofeng Yan; Xiaohua Jiang; Ihtisham Bukhari; Furhan Iqbal; Howard J Cooke; Qinghua Shi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells.

Authors:  Nadire Duru; Ramkishore Gernapudi; Gabriel Eades; Richard Eckert; Qun Zhou
Journal:  Curr Pharmacol Rep       Date:  2015-06-01

9.  MIR146A inhibits JMJD3 expression and osteogenic differentiation in human mesenchymal stem cells.

Authors:  Jessica M Huszar; Christopher J Payne
Journal:  FEBS Lett       Date:  2014-04-12       Impact factor: 4.124

10.  Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication.

Authors:  Irena Misiewicz-Krzeminska; María E Sarasquete; Dalia Quwaider; Patryk Krzeminski; Fany V Ticona; Teresa Paíno; Manuel Delgado; Andreia Aires; Enrique M Ocio; Ramón García-Sanz; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.